Literature DB >> 17548532

Creating an immune-privileged site using retinal progenitor cells and biodegradable polymers.

Tat Fong Ng1, Erin Lavik, Hiroshi Keino, Andrew W Taylor, Robert S Langer, Michael J Young.   

Abstract

We describe the creation of local immune privilege (IP) using retinal progenitor cells (RPCs) and biodegradable polymers. Murine RPCs were seeded on poly(lactic-coglycolic acid) polymers to generate composite grafts. Composites or RPCs alone were transplanted into allogeneic kidney capsules. Grafts survived at all time points, differentiating into neurons and astrocytes. Upon treatment with interferon gamma (IFNgamma), major histocompatibility complex antigens were upregulated. Although 10% of IFNgamma-treated RPC grafts survived 14 days, 66% of the IFNgamma-treated composites survived in part by producing immune suppressive factors transforming growth factor-beta2, Fas ligand, and indoleamine 2,3-dioxygenase. The composites were assayed for delayed-type hypersensitivity (DTH) by seeding composites with antigen-presenting cells incubated with ovalbumin. This resulted in suppression of ovalbumin-specific DTH, indicating that composite grafts consisting of biodegradable polymers and central nervous system progenitor cells can be used to generate local IP. This technology may be used to promote the survival of nonprivileged grafts (e.g., pancreas, liver, or skin). Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548532     DOI: 10.1634/stemcells.2006-0780

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  6 in total

1.  Effects of extracellular matrix and neighboring cells on induction of human embryonic stem cells into retinal or retinal pigment epithelial progenitors.

Authors:  Jie Gong; Ofer Sagiv; Hui Cai; Stephen H Tsang; Lucian V Del Priore
Journal:  Exp Eye Res       Date:  2008-03-28       Impact factor: 3.467

Review 2.  Engineering therapies in the CNS: what works and what can be translated.

Authors:  Andrew J Shoffstall; Dawn M Taylor; Erin B Lavik
Journal:  Neurosci Lett       Date:  2012-02-04       Impact factor: 3.046

3.  Engineering retinal progenitor cell and scrollable poly(glycerol-sebacate) composites for expansion and subretinal transplantation.

Authors:  Stephen Redenti; William L Neeley; Santiago Rompani; Sunita Saigal; Jing Yang; Henry Klassen; Robert Langer; Michael J Young
Journal:  Biomaterials       Date:  2009-04-09       Impact factor: 12.479

4.  Combining chondroitinase ABC and growth factors promotes the integration of murine retinal progenitor cells transplanted into Rho(-/-) mice.

Authors:  Jian Ma; Mostafa Kabiel; Budd A Tucker; Jian Ge; Michael J Young
Journal:  Mol Vis       Date:  2011-06-29       Impact factor: 2.367

5.  Functional and morphological analysis of the subretinal injection of human retinal progenitor cells under Cyclosporin A treatment.

Authors:  Rui Huang; Petr Baranov; Kunbei Lai; Xinmei Zhang; Jian Ge; Michael J Young
Journal:  Mol Vis       Date:  2014-09-19       Impact factor: 2.367

Review 6.  Ocular Immune Privilege and Transplantation.

Authors:  Andrew W Taylor
Journal:  Front Immunol       Date:  2016-02-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.